Related references
Note: Only part of the references are listed.Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer
Zeting Yuan et al.
BRITISH JOURNAL OF CANCER (2020)
Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness
Behzad Mansoori et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel
Marjan Aghajani et al.
MOLECULAR BIOLOGY REPORTS (2020)
CD133: beyond a cancer stem cell biomarker
Amir Barzegar Behrooz et al.
JOURNAL OF DRUG TARGETING (2019)
CD133 as a regulator of cancer metastasis through the cancer stem cells
Geou-Yarh Liou
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)
Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells
Ruiqi Lu et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Potential mechanisms of CD133 in cancer stem cells
Jae-Woo Jang et al.
LIFE SCIENCES (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
The Interaction between Cancer Stem Cell Marker CD133 and Src Protein Promotes Focal Adhesion Kinase (FAK) Phosphorylation and Cell Migration
Chanjuan Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation
Chen Li et al.
ONCOTARGET (2016)
STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC
Sarani Ghoshal et al.
HEPATOBILIARY SURGERY AND NUTRITION (2016)
Worldwide burden of colorectal cancer: a review
Pasqualino Favoriti et al.
UPDATES IN SURGERY (2016)
RNAi Therapies: Drugging the Undruggable
Sherry Y. Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
CD133 silencing inhibits sternness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stern cells
Xi Lan et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013)
Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment
Hejia Zhang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2013)
Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation
Anthony B. Mak et al.
CELL REPORTS (2012)
CD133/Src Axis Mediates Tumor Initiating Property and Epithelial-Mesenchymal Transition of Head and Neck Cancer
Yu-Syuan Chen et al.
PLOS ONE (2011)
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma
Zheng Zhu et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
